BioSpace News Archive

Merck, known as MSD outside the United States and Canada, and the Institute for Systems Biology, announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines.

Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, announces the appointment of Labquality Oy as a distributor of its Quality Assessment Products in seven countries.

Lexicon Pharmaceuticals, Inc., reported financial results and provided a business update for the three months ended March 31, 2020.

Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group

Community Blood Centers Nationwide Remain at the Forefront of the National Response Efforts to Increase Access to COVID-19 Convalescent Plasma [27-April-2020] WASHINGTON , April 27, 2020 /PRNewswire/ -- America’s Blood Centers and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Resp

Study to Determine Whether Pacritinib Can Prevent Progression to Acute Respiratory Distress Syndrome and Mechanical Ventilation

Castle Biosciences, Inc. announced that it will release its financial results for the first quarter ended March 31, 2020, after the close of market on Monday, May 11, 2020.

Lead program, PARP7 inhibitor RBN-2397, demonstrates complete tumor regression in preclinical cancer models

The US Food and Drug Administration approved a label update in the US for AstraZeneca’s LOKELMA® to include a dosing regimen specifically to treat hyperkalemia in patients with end-stage renal disease on chronic hemodialysis.

New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo High local concentrations of funapide, the active ingredient in FX301, were measured at the site of administration for the duration of the study, consistent with the creation of a depot providing controlled drug release Electronic poster presentation now available on the American Society of Regional Anesthesia and Acute Pain Me